STATEMENT OF NEED
Among the estimated 236,740 new cases of lung cancer reported in the United States annually, approximately 84% are classified as non–small cell lung cancer (NSCLC) (ACS, 2022). The most frequent genomic aberrations identified in patients with NSCLC are epidermal growth factor receptor (EGFR) mutations, approximately 2% to 10% of which are classified as exon 20 insertion mutations (Kumari et al, 2019; Meador et al, 2021). EGFR exon 20 insertion mutations comprise a heterogenous group frequently associated with resistance to first- and second-line EGFR tyrosine kinase inhibitor (TKI) therapy (NCCN, 2022). The timely diagnosis of EGFR exon 20 insertion–mutant NSCLC is complicated by confusion surrounding guideline recommendations for molecular profiling and genomic testing. Selecting the optimal treatment for patients with this mutation remains a challenge for clinicians, particularly in light of the rapid pace of clinical research surrounding novel therapies. In this activity, an expert faculty member will discuss the clinical implications of EGFR exon 20 status in decision making, the role and timing of molecular profiling in diagnosis, and the efficacy and safety profiles of novel small molecular inhibitors in the treatment of advanced EGFR exon 20 insertion–mutant NSCLC.
Oncologists, pulmonologists, pathologists, histologists, nurse practitioners, physician associates, oncology nurses, and other health care professionals involved in the treatment of patients with NSCLC.
Upon completion of this activity, participants should be able to:
- Differentiate predictive and prognostic biomarkers that can guide individualized management of advanced EGFR exon 20 insertion–mutant NSCLC
- Appraise guideline recommendations for molecular diagnosis in advanced NSCLC
- Evaluate emerging efficacy and safety data on novel selective small molecule inhibitors for the treatment of advanced EGFR exon 20 insertion–mutant NSCLC
Alexander Drilon, MD (Chairperson)
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Narjust Duma, MD
Associate Director, Cancer Care Equity Program
Thoracic Medical Oncologist
Assistant Professor of Medicine
Harvard Medical School
There is no fee to participate in or claim CME/NCPD credit for this activity.
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.9 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.0 ILNA point toward:
- Care Continuum (ONC®, CBCN®, AOCNP®)
- Oncology Nursing Practice (OCN®)
- Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
- Treatment (OCN®, CBCN®, AOCNP®)
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies.
The i3 Health planners, reviewers, and managers have nothing to disclose.
Alexander Drilon, MD, discloses that he has served on an advisory board/panel for AbbVie, ArcherDX, AstraZeneca, AXIS, BeiGene, BerGenBio, Blueprint Medicines, Chugai, Elevation Oncology, EMD Serono, EPG Health, Exelixis, Harborside, Helsinn, Ignyta/Genentech/Roche, Jiangsu Hengrui, Liberum, Loxo/Bayer/Lilly, MBrace Therapeutics, Melendi, Merus, Monopteros, MORE Health, Novartis, Nuvalent, Ology Bioservices, Pfizer, Remedica, Repare Therapeutics, RV Pharma, Takeda/ARIAD/Millennium, Turning Point Therapeutics, Tyra Biosciences, and Verastem. He has also received research support or other financial or material support from Boehringer Ingelheim, Exelixis, GlaxoSmithKline, Merck, Merus, Pfizer, PharmaMar, Puma, Taiho Oncology, and Teva.
Narjust Duma, MD, discloses that she has served on an advisory board or panel for AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Mirati, NeoGenomics, and Pfizer.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.